Clinical trials: Stage III Non-small Cell Lung Cancer
- Condition Stage III Non-small Cell Lung Cancer
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Non Small Cell Lung Cancer
FHND9041 Versus Afatinib for Non-small Cell Lung Cancer
The goal of this clinical trial is to evaluate the effectiveness and safety of FHND9041 compared to afatinib as first-line treatments for epidermal growth factor receptor mutation-positive (EGFRm+) locally advanced or metastatic…
- Trial name
- FHND9041 (NCT06759857)
- Testing
- FHND9041, Afatinib
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)
Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients
This study aims to investigate the expression of Melanoma-associated antigen 3 (MAGE-A3), Melanoma-associated antigen C2 (MAGE-C2), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), L antigen family member 1 (LAGE-1)…
- Trial name
- NCT01837511
- Testing
- Data acquisition and analysis
- Where
- 3 sites in Singapore, South Korea
- Volunteers
- 377 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)
First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy in Asia Area
- Trial name
- NCT04529564
- Where
- 12 sites in Taiwan
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery
This is a multicenter, observational cohort study in China with both primary prospective data collection and retrospective collection of prior treatment information from medical records, which enrolls and follows patients who are…
- Trial name
- NCT05872763
- Where
- 12 sites in China
- Volunteers
- 901 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer, Lung Cancer, Cancer
Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China
The purpose of this observational study is to describe patient and disease characteristics as well as treatment patterns in Chinese patients with unresectable stage IIIB or IV non-small cell lung cancer (NSCLC).
- Trial name
- NCT02458651
- Testing
- No intervention
- Where
- 11 sites in China
- Volunteers
- 1,378 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
Reveal the Patterns of Presentation, Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia:
A retrospective, multi-centre, observational study to describe the treatment patterns, the demographic, clinical outcomes, treatment effectiveness, and healthcare resource utilization (HCRU) for patients diagnosed with primary…
- Trial name
- REVEAL (NCT04836975)
- Where
- Saudi Arabia
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for…
- Trial name
- NCT00050960
- Testing
- bexarotene with carboplatin and paclitaxel, carboplatin and paclitaxel
- Where
- 154 sites in United States, Austria and 4 more
- Volunteers
- 612 people
- Sponsor
- Eisai Inc.
Non-small Cell Lung Cancer
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for…
- Trial name
- NCT00050973
- Testing
- bexarotene
- Where
- 77 sites in United States, Australia and 9 more
- Volunteers
- 623 people
- Sponsor
- Eisai Inc.
Non-Small Cell Lung Cancer
A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients
Taxotere has been approved by the FDA and is considered a standard treatment for patients with lung cancer who have failed prior platinum-containing regimens.
- Trial name
- NCT00085826
- Testing
- Exisulind
- Where
- 114 sites in United States
- Volunteers
- 600 people
- Sponsor
- Astellas Pharma Inc
Cachexia
Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.
The purpose of this study is to assess if Gtx-024 is effective in increasing lean body mass in subjects with muscle wasting related to cancer.
- Trial name
- NCT00467844
- Testing
- GTx-024
- Where
- 52 sites in United States, Canada
- Volunteers
- 159 people
- Sponsor
- GTx
Non-small-cell Lung Cancer (NSCLC)
A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients
This large multinational, non-interventional study (NIS), will retrospectively collect data derived from established medical records over a period of up to approximately 6 years (2013 to 2018), building a platform to capture and…
- Trial name
- KINDLE (NCT03725475)
- Where
- 32 sites in Argentina, Chile and 8 more
- Volunteers
- 3,111 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC
This observational study is designed to assess the long term safety of the durvalumab treatment period including subsequent treatment period and demonstrate the efficacy of patients treated with durvalumab following…
- Trial name
- AYAME (NCT03995875)
- Where
- 43 sites in Japan
- Volunteers
- 529 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).
The primary objective of the study is to collect epidemiological data on EGFR mutation status [M+(mutation positive), M-(mutation negative)] in a population of predominantly Caucasian ethnicity, and to correlate EGFR mutation…
- Trial name
- REASON (NCT01153399)
- Where
- 9 sites in Greece
- Volunteers
- 589 people
- Sponsor
- AstraZeneca
NSCLC (Advanced Non-small Cell Lung Cancer)
A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This is a Randomized, Double-Blind, Multicenter, Phase II/III Study to Evaluate HLX37 (Recombinant Human Anti-PD-L1 and Anti-VEGF Bispecific Antibody) in Combination with Chemotherapy Versus Pembrolizumab in Combination with…
- Trial name
- NCT07865910
- Testing
- Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion)
- Where
- 16 sites in China
- Volunteers
- 1,438 people
- Sponsor
- Shanghai Henlius Biotech